ClickOptions today launched a crypto options venue built to compress the true all-in cost of trading.ClickOptions today launched a crypto options venue built to compress the true all-in cost of trading.

ClickOptions Launches A Crypto Options Venue

Clickoptions Launches A Crypto Options Venue Built For Better Prices, Smoother Trades, And Radical Transparency

ClickOptions today launched a crypto options venue built to compress the true all-in cost of trading. The platform combines low commissions, a flow-implied, vault-aware pricing engine designed to push premiums toward fair value or better, and a central order book with institutional custody.

A hybrid model, the team calls CeDeFi: centralized execution, decentralized liquidity.

Alongside launch, ClickOptions is opening an Airdrop Farming campaign and previewing plans for a $50M token sale to accelerate growth and liquidity.

What’s new

Flow-implied pricing engine

Adjusts implied volatility using order flow, sentiment, and market skew to bring premiums to fair value or better, often reducing the effective spread vs traditional statistical models.

Public transparency by default

ClickOptions will publish dated Spread/Depth Benchmark Cards that show the true all-in price at real trading sizes. Participants can audit the claims week after week.

Vault-backed liquidity (coming soon)

A shared risk pool underwrites outcomes; liquidity providers earn from real trading activity. Traders see fairer prices; the vault has clear safety rails (capital thresholds, proportional withdrawals, dynamic settlement fees). The first underwriting capital is secured, with a dedicated announcement to follow.

CeDeFi architecture

Central order book + KYC gating + third-party custody for reliability and compliance; decentralized liquidity and yield for scalability.

Community programs and token utility Airdrop Farming (live)

An open-ended points program that rewards useful participation, learning, testing, creating educational content, and (when live) executing guided trades, toward future airdrop eligibility.

Extras may include fee credits, gated access, and competition perks (where applicable).

Token utility (future)

The upcoming token (ticker TBD) powers:

  • Fee discounts on the already low base commission (up to 45%)
  • Vault yield boosts for liquidity providers
  • A policy-driven buy/burn mechanism (“Regen Fund”) funded by platform revenue

Token sale (preview)

ClickOptions is planning a $50M token sale to fund execution of its roadmap and liquidity programs.

Availability and roadmap

Prime launch: With majors first, expanding alt coverage as depth scales.

Benchmarks and signals: live at/around launch; weekly public cards continue post-launch.

Post-launch: expanded option chain (multiple alts), external LPs, and transparent risk dashboards; long-term roadmap includes a non-custodial path.

Media / Demo / Assets

Website: https://clickoptions.ai/

Press contact: [email protected]

X: https://x.com/clickoptions_ai

LinkedIn: https://www.linkedin.com/company/clickoptions

Telegram (announcements): t.me/clickoptions

Docs (GitBook): https://docs.clickoptions.ai/

About ClickOptions

ClickOptions is a crypto options venue that makes options cheaper, deeper, and clearer, combining flow-implied pricing, vault-backed liquidity, and institutional-grade execution. The team has shipped institutional trading systems, scaled Web3 GTMs, and delivered fintech products end-to-end.

ClickoptionsClickoptions

This article was originally published as ClickOptions Launches A Crypto Options Venue on Crypto Breaking News – your trusted source for crypto news, Bitcoin news, and blockchain updates.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26